Format

Send to

Choose Destination

See 1 citation found by title matching your search:

See comment in PubMed Commons below
Cancer Treat Rev. 2014 Apr;40(3):366-75. doi: 10.1016/j.ctrv.2013.08.001. Epub 2013 Aug 8.

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

Author information

1
Área Clínica de Oncología Ginecológica, Fundación Instituto Valenciano de Oncología, Prof. Baguena, 19, 46009 Valencia, Spain. Electronic address: apoveda@fivo.org.
2
Département d'Oncologie Médicale Adulte, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France. Electronic address: isabelle.ray-coquard@lyon.unicancer.fr.
3
Área Clínica de Oncología Ginecológica, Fundación Instituto Valenciano de Oncología, Prof. Baguena, 19, 46009 Valencia, Spain. Electronic address: nachete54@hotmail.com.
4
Área Clínica de Oncología Ginecológica, Fundación Instituto Valenciano de Oncología, Prof. Baguena, 19, 46009 Valencia, Spain; Laboratorio de Biología Molecular, Fundación Instituto Valenciano de Oncología, Prof. Baguena, 19, 46009 Valencia, Spain. Electronic address: jalopez@fivo.org.
5
Dipartimento di Medicina e Chirurgia Interdisciplinare, Università Milano-Bicocca and Divisione di Ginecologia Oncologica Medica, Via Ripamonti, 435-20141 Milano, Italy. Electronic address: nicoletta.colombo@ieo.it.

Abstract

Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high response rates to the standard front-line treatment for advanced disease with cytoreductive surgical debulking, followed by platinum/taxane-based chemotherapy, most patients eventually relapse developing drug-resistant disease. Owing to the molecular heterogeneity, genetic instability and mutagenicity of OC, increases in survival might be achieved by translating recent insights at the morpho-molecular levels to individual therapeutic strategies. Several emerging treatments have been shown to be active in platinum-sensitive (PS) recurrent OC (ROC), but an optimal strategy still has not been established. Based on the recent results, it is likely that the introduction of novel non-platinum based chemotherapies and molecular targeted therapies will have a major impact on the management of ROC. Some current strategies are focused on the extension of platinum-free interval (PFI) in patients with PS, particularly in those with partially PS disease. Apparently, the PFI extension by an effective non-platinum intervention, such as trabectedin plus pegylated liposomal doxorubicin (PLD), may reduce cumulative platinum-induced toxicities leading to longer survival after the reintroduction of subsequent platinum. The introduction of novel therapies, such as the antiangiogenic monoclonal antibody bevacizumab, opens a new field of targeted therapies in this indication. In this review, we aim to outline the therapeutic potential of new emerging approaches, particularly the role of non-platinum therapy with trabectedin in combination with PLD in patients with PS ROC.

KEYWORDS:

PLD; Platinum-sensitive; Recurrent ovarian cancer; Trabectedin

PMID:
24296108
DOI:
10.1016/j.ctrv.2013.08.001
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center